Job title: Chief Executive Officer
Dr. Tom Hughes has more than 30 years of industry experience in the development and commercialization of pharmaceutical products. Prior to joining Navitor, Dr. Hughes served as President and Chief Scientific Officer of Zafgen and previously led Zafgen as CEO from 2008 to 2017. During this time, Dr. Hughes established Zafgen as a leading biotechnology company working in the area of rare and prevalent metabolic disorders and led the company through its Initial Public Offering in 2014. Prior to Zafgen, Dr. Hughes held several positions at Novartis including Global Head of the Cardiovascular and Metabolic Diseases Therapeutic Area at the Novartis Institutes for BioMedical Research in Cambridge, MA. In these roles, he oversaw many drug discovery and development projects targeting major global aging-related health issues including obesity, diabetes, and heart disease. Dr. Hughes currently serves as a member of the Board of Directors of miRagen Therapeutics, Inc., and is a member of several scientific and strategic advisory boards, including Broadview Ventures, HotSpot Therapeutics, and FaunaBio.
Dr. Hughes holds a Ph.D. in nutritional biochemistry from Tufts University, an M.S. in zoology from Virginia Polytechnic Institute & State University and a B.A. in biology from Franklin and Marshall College
Examine Polycystic Kidney Disease as a First Indication for Development of the mTORC1-selective Rapamycin Analog NV-20494 2:45 pm
Explore Kidney cyst formation and its relationship to mTORC1 dysregulation Overview of prior experience in polycystic kidney disease with rapamycin and everolimus, and mechanistic considerations related to the importance of mTORC1 selectivity Investigate approaches to gathering insight regarding impact of mTORC1 inhibition on endpoints of relevance to longevityRead more
day: Day Two